Lexaria Bioscience (LEXX) Capital Leases (2021 - 2024)

Lexaria Bioscience has disclosed Capital Leases across 4 years of filings, most recently posting $109319.0 for Q3 2024.

• Capital Leases for Q3 2024 came in at $109319.0, down 19.72% year-over-year; the trailing twelve-month figure through Aug 2024 was $109319.0 (down 19.72% YoY), and the FY2024 annual result was $109319.0, down 19.72% from the prior year.
• Capital Leases came in at $109319.0 for Q3 2024 at Lexaria Bioscience, down from $115327.0 in the prior quarter.
• In the past five years, Capital Leases ranged from a high of $142587.0 in Q2 2023 to a low of $7401.0 in Q3 2022.
• The 4-year median for Capital Leases is $118906.5 (2024), against an average of $101599.9.
• Across the five-year window, Capital Leases slumped 85.19% in 2022 and soared 1739.93% in 2023, its largest moves.
• Lexaria Bioscience's Capital Leases stood at $49989.0 in 2021, then plunged by 85.19% to $7401.0 in 2022, then jumped by 1649.99% to $129517.0 in 2023, then retreated by 15.59% to $109319.0 in 2024.
• The last three Capital Leases figures came in at $109319.0 (Q3 2024), $115327.0 (Q2 2024), and $122486.0 (Q1 2024), per Business Quant data.